west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "靶点" 18 results
  • Nuclear Factor Kappa B and Liver Injury

    Objective To summarize the role of nuclear factor kappa B (NF-κB) in the occurrence and progression of various sorts of liver injury. Methods Literatures on the structures, property of molecular biology and function of NF-κB, as well as its relationships with liver injury were collected and reviewed. Results NF-κB was an important nuclear factor existed in cells widely distributed in most cell types. The activation of NF-κB was induced by various sorts of liver injury. The activated NF-κB could affect the liver injury by regulating cytokines, adhesion molecules, and activating factor involving in immunologic reaction, inflammatory reaction and the apoptosis. Conclusion  NF-κB plays an important role during the occurrence and progression of liver injury, and may become a new target in the treatment of liver injury.

    Release date:2016-08-28 04:08 Export PDF Favorites Scan
  • 多靶点酪氨酸激酶抑制剂的临床应用进展

    蛋白酪氨酸激酶介导的信号传导通路是目前研究较多且效果明显的抗肿瘤药物靶点,多靶点酪氨酸激酶抑制剂能够抑制多个信号传导通路,诱导肿瘤细胞的凋亡,阻断新生血管的生成,抑制肿瘤细胞的增殖,是近几年上市的主要抗肿瘤药物。现对多靶点酪氨酸激酶抑制剂的临床应用、注意事项及目前研究进展进行综述。

    Release date:2016-09-07 02:37 Export PDF Favorites Scan
  • Selectivity Individualization of Curing Lumbar Intervertebral Disc Protrusion by Combined Minimally Invasive Techniques

    摘要:目的:探讨联合应用激光汽化减压(percutaneous laser disc discompression,PLDD)、射频热凝靶点消融、臭氧注射治疗腰椎间盘突出症的的个体化选择。方法: 自2006年6月,在CT引导下选择性联合应用PLDD、射频和臭氧治疗腰椎间盘突出症患者267例,突出椎间盘的特点个体化选择穿刺路径和治疗方法;其中PLDD联合臭氧治疗92例(A组),射频联合臭氧治疗67例(B组),PLDD、射频和臭氧三者联合治疗108例(C组)。结果:所有患者均顺利完成手术,于术后1周、1个月,3个月及6个月随访记录VAS评分和Macanab优良率。三组患者VAS评分经方差分析,手术前、后有显著性差异(Plt;0.05),术后1周至6个月的VAS评分统计无显著性差异(Pgt;0.05);术后三组间VAS评分、Macanab优良率比较无显著性差异(Pgt;0.05)。结论: 选择性联合应用微创技术进行个体化的立体治疗,具有扩大微创手术适应症、提高手术疗效的优势,值得推广和利用。Abstract: Objective: To investigate the selectivity and individualization of using percutaneous laser disc discompression(PLDD) and ozone injection combined with radiofrequency thermocoagulation and target ablation curing lumbar intervertebral disc protrusion. Methods: From June 2006, 267 lumbar disc herniation cases were operated that guided by CT, the characteristic of the liable disc was confirmed by magnetic resonance imaging and CT before the procedure. 92 cases (A group) were treated by PLDD combined with ozone injection,67 case were treated by radiofrequency thermocoagulation and target ablation combined with ozone injection, 108 cases were treated by PLDD and ozone injection combined with radiofrequency thermocoagulation and target ablation. Results: All case been successfully operated, the theraptic effect was evaluated by comparing the value of VAS and excellent and good rate of therapy at preoperation and at 1 week, 1month,3 months, 6 months after operation. The value of VAS in three groups at postoperation were remarkably lower than preoperation (Plt;0.05). The excellent and good rate of therapy at 6 months was respectively 94.5% in group A,94.0% in group B and 95.4% in group C,no significant difference was observed between the three groups(Pgt;0.05).Conclusion: The selectivity and individualization of using PLDD and ozone injection combined with radiofrequency thermocoagulation and target ablation curing lumbar intervertebral disc protrusion can enlarge the indication and improve the clinical curative effect, it should be spreaded in clinic.

    Release date:2016-09-08 10:12 Export PDF Favorites Scan
  • Therapeutic Targets of Pancreatic Cancer

    ObjectiveTo summarize the therapeutic targets of pancreatic cancer (PC). MethodsThe related literatures about the therapeutic targets of PC were reviewed. ResultsPC was one of the most challenging tumor in worldwide, and was characterized as a highly aggressive disease with poor overall prognosis and a high mortality rate. The hallmark of PC was its poor response to radio-and chemo-therapy. Current chemotherapeutic regimens could not provide substantial survival benefit with a clear increase in overall survival. Recently, several new approaches which could significantly improve the clinical outcome of PC had been described, involving signal-transduction pathways, immune response, stroma reaction, and epigenetic changes. ConclusionsMany therapeutic targets are involved in the treatment of PC. As current therapies failed to significantly improve the progression and the survival of PC, new therapeutic approaches and clinical studies are strongly required.

    Release date: Export PDF Favorites Scan
  • Efficacy and safety of tyrosine kinase inhibitors combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a meta-analysis

    Objective To systematically review the efficacy and safety of tyrosine kinase inhibitors combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer(NSCLC). Methods An electronically search was conducted in The Cochrane Library, PubMed and EMbase databases from inception to December 2016 to collect randomized controlled trials (RCTs) about tyrosine kinase inhibitors combined with chemotherapy versus chemotherapy for NSCLC. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using RevMan 5.3 software. Results A total of 12 RCTs involving 6 559 patients were finally included. The results of meta-analysis showed that: The median progression free survival (PFS) (HR=0.86, 95%CI 0.81 to 0.91, P<0.001) and objective response rate (ORR) (HR=1.43, 95%CI 1.20 to 1.70,P<0.001) of tyrosine kinase inhibitors combined with chemotherapy were significantly longer than those of the chemotherapy group. There were no significant differences between two groups in incidence of median overrall survival (OS) (HR=0.91, 95%CI 0.82 to 1.00,P=0.06), fatigue (RR=1.03, 95%CI 0.97 to 1.11, P=0.33), dyspnea (RR=1.01, 95%CI 0.91 to 1.13, P=0.82) and cough (RR=1.01, 95%CI 0.89 to 1.15, P=0.91). However, the incidence of neutrocytopenia (RR=1.16, 95%CI 1.05 to 1.28, P=0.003), thrombocytopenia (RR=1.46, 95%CI 1.23 to 1.73, P<0.001), diarrhea and hypertension (RR=2.91, 95%CI 2.28 to 3.71,P<0.001) of tyrosine kinase inhibitors combined with chemotherapy group were significantly higher than those of the chemotherapy group. The tyrosine kinase inhibitors combined with chemotherapy group had lower rate of anemia (RR=0.86, 95%CI 0.75 to 0.98,P=0.03). Conclusion Compared with chemotherapy alone, tyrosine kinase inhibitors combined with chemotherapy can improve the median PFS and ORR while it can be used as a treatment for advanced non-small cell lung cancer patients. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.

    Release date:2017-10-16 11:25 Export PDF Favorites Scan
  • 微小 RNA 和伴海马硬化的内侧颞叶癫痫:人类海马全微小 RNA 组谱

    内侧颞叶癫痫(mesial temporal lobe epilepsy, mTLE)是一种严重的以反复癫痫发作为特征的神经系统疾病。mTLE 通常伴有海马神经元变性导致的海马硬化(Hippocampal sclerosis,HS), 它是与 mTLE 患者耐药性相关的最常见的形态学改变。对 mTLE+HS 的认识不足使其治疗复杂化。mTLE+HS 的潜在病理机制可能涉及异常的基因表达调控,包括涉及微小 RNA(microRNA, miRNA)的转录后网络。 miRNA 表达调控在包括癫痫的多种疾病中都有报道。但是,mTLE+HS 的 miRNA 谱暂未被完全了解,需要进一步解决。在此,为了揭示 miRNA 的异常表达,我们关注了 33 例 mTLE+HS 患者和 9 具对照者尸检的海马 miRNA 分析。研究中,通过联合两种不同的 miRNA 分析方法,以及下一代测序技术和 miRNA 特异性实时定量聚合酶链式反应,我们显著降低了技术相关的偏移(最常见的是 miRNA 分析数据的假阳性)。这些方法结合起来明确并验证了 20 例癫痫患者海马中 miRNA 的表达改变。在 mTLE+HS 患者中,有 19 例 miRNA 上调,1 例下调。其中 9 种 miRNA 以往没有报道与癫痫有联系,19 例异常表达的 miRNA 可能调节与癫痫相关的靶点和通路(例如:钾离子通道,γ-氨基丁酸,神经营养因子信号传导和轴突导向)。研究通过明确 miRNA 在 mTLE+HS 中表达,扩展了当前对 mTLE+HS 中 miRNA 介导的基因表达调控的认知,包括 9 个新发现的 miRNA 异常表达及其可能的靶点。 这些发现进一步提升了基于 microRNA 的生物标志物或疗法的可能性。

    Release date:2018-03-20 04:09 Export PDF Favorites Scan
  • A comparative cross-sectional study of Chinese and American lung caner drug trial in 2019

    ObjectiveTo compare the current status of clinical studies regarding lung cancer between China and the United States in 2019, and to indicate the weakness, trend and future development direction of clinical studies drug treatment in China.MethodsThe data of lung cancer clinical studies from January 1st to November 30th, 2019 in China and the United States were retrieved and analyzed through Informa pharmaprojects database.ResultsThe United States was superior on the number of projects (128 vs. 156) and research institutions (743 vs. 2 250). Compared with the United State, there were more phase Ⅲ confirmatory researches (19.5% vs. 10.3%), bioequivalent drug researches (3.1% vs. 0%), and researches initiated by academic institutions (39.8% vs. 28.1%) in China. The United States exhibited advantages in phaseⅠ andⅠ/Ⅱstudies (25.8% vs. 60.3%), immunodrugs (49.2% vs. 60.3%), primary tested drug ratio (61.7% vs. 93.6%), targets abundance (32.9% vs. 69.6%), and chimeric antigen receptor-T (CAR-T, 0.7% vs. 7.1%).ConclusionCompared with the United States, China should pay more attention to innovative drug investigations in early phase of clinical studies, especially novel immune agents, vaccines, and CAR-T.

    Release date:2020-03-25 09:52 Export PDF Favorites Scan
  • Research progress of circRNAs in thyroid papillary carcinoma

    ObjectiveTo summarize the role of circular RNA (circRNAs) in thyroid papillary carcinoma (PTC) and the emphasis of future research.MethodRelevant literatures in recent years about the biological function of circRNA and its role in PTC were reviewed.ResultscircRNAs had abnormal expression in PTC tissues. Besides, by working as miRNA sponges or interacting with RNA-binding proteins, circRNAs regulated the expression of proteins that were associated with cell proliferation, apoptosis, invasion, and metastasis, which could affect the biological characteristics of tumor cells.ConclusioncircRNAs are expected to be the biomarkers for early diagnosis of PTC or potential targets for PTC therapy and provid therapeutic bases to prevent PTC.

    Release date:2020-07-26 02:35 Export PDF Favorites Scan
  • Research progress of circRNA in gastric cancer

    ObjectiveTo summarize the recent research progress of circRNA in gastric cancer, and to explore the clinical value of circRNA as new therapeutic target and diagnostic or prognostic biomarker for gastric cancer.MethodThe studies on circRNA and related literatures in gastric cancer were reviewed.ResultsAs a new member of the non-coding RNA family, circRNA played a key role in regulating the proliferation, invasion, migration, apoptosis, and therapeutic resistance of gastric cancer cells. At the same time, based on the stability and tissue-specific characteristics, circRNA possessed great potential as biomarker for early diagnosis or prognosis evaluation of gastric cancer.ConclusionscircRNA plays an important role in the initiation and progression of gastric cancer. As a diagnostic and prognostic biomarker and a new therapeutic target for gastric cancer, circRNA has great potential for clinical transformation.

    Release date: Export PDF Favorites Scan
  • Research progress of molecular targeted therapy for pancreatic cancer

    Objective To summarize the progress in related basic research of molecular targeted therapy in pancreatic cancer. Method The relevant literatures on oncogenes, epigenome, tumour microenvironment and immunotherapy in recent years at home and abroad were reviewed. ResultsIn basic research, molecularly targeted drugs had shown some efficacy in the treatment of progression of pancreatic cancer, however, in clinical trials, more satisfactory results were not achieved. Conclusion Molecularly targeted therapies for pancreatic cancer are still at a preliminary stage of exploration, and basic research has not yet been effectively translated clinically, which requires further exploration efforts in subsequent studies to provide a more solid and reliable basis for precise treatment of pancreatic cancer and achieve better clinical benefits.

    Release date: Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content